Table Info

Table 3.

The challenges facing telemedicine in BC management after the pandemic

Challenges	Most concerned groups
Digital accessibility [26, 50, 53]	Older patients Ethnic groups Patients with sensory disabilities
Infrastructure [26]	Remote regions Developing countries
Staff training and licensing [36]	Small remote centers Developing countries
Reimbursement [51, 54]	Low-income households States with no telehealth regulations

Declarations

Author contributions

JZ: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. ER: Investigation, Writing—review & editing. PL and RE: Data curation, Writing—review & editing. BP: Conceptualization, Methodology, Validation, Writing—review & editing, Supervision. All authors read and approved the submitted version.

Conflicts of interest

BP: Consulting/advisor: Puma Biotechnology, Novartis, Myriad Genetics, Pierre Fabre; Personal fees: Novartis, AstraZeneca, MSD Oncology, Pfizer; Research funding: Daiichi-Sankyo, Puma Biotechnology, Novartis, Merus, Pfizer, AstraZeneca. The other authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. [DOI] [PubMed]

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. Erratum in: CA Cancer J Clin. 2020;70:313. [DOI] [PubMed]

Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72:524–41. [DOI] [PubMed]

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al.; CONCORD Working Group. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–75. [DOI] [PubMed] [PMC]

Xu S, Liu Y, Zhang T, Zheng J, Lin W, Cai J, et al. The global, regional, and national burden and trends of breast cancer from 1990 to 2019: results from the global burden of disease study 2019. Front Oncol. 2021;11:689562. [DOI] [PubMed] [PMC]

Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95:1130. [DOI] [PubMed] [PMC]

The global breast cancer initiative (GBCI) [Internet]. WHO; c2021 [cited 2023 Jan 28]. Available from: https://www.who.int/publications/m/item/the-global-breast-cancer-initiative-gbci

Duffy SW, Tabár L, Yen AM, Dean PB, Smith RA, Jonsson H, et al. Mammography screening reduces rates of advanced and fatal breast cancers: results in 549,091 women. Cancer. 2020;126:2971–9. [DOI] [PubMed] [PMC]

Ren W, Chen M, Qiao Y, Zhao F. Global guidelines for breast cancer screening: a systematic review. Breast. 2022;64:85–99. [DOI] [PubMed] [PMC]

10.

Pérez-López ME, García-Gómez J, Alves MT, Paradela A, García-Mata J, García-Caballero T. Ki-67 is a prognostic marker for hormone receptor positive tumors. Clin Transl Oncol. 2016;18:996–1002. [DOI] [PubMed] [PMC]

11.

McVeigh TP, Kerin MJ. Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer. Breast Cancer (Dove Med Press). 2017;9:393–400. [DOI] [PubMed] [PMC]

12.

Leclerc AF, Jerusalem G, Devos M, Crielaard JM, Maquet D. Multidisciplinary management of breast cancer. Arch Public Health. 2016;74:50. [DOI] [PubMed] [PMC]

13.

Coronavirus disease (COVID-19) pandemic [Internet]. WHO; c2023 [cited 2023 Jan 29]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019

14.

ElGohary GM, Hashmi S, Styczynski J, Kharfan-Dabaja MA, Alblooshi RM, de la Cámara R, et al. The risk and prognosis of COVID-19 infection in cancer patients: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2022;15:45–53. [DOI] [PubMed] [PMC]

15.

Rodriguez GM, Ferguson JM, Kurian A, Bondy M, Patel MI. The impact of COVID-19 on patients with cancer: a national study of patient experiences. Am J Clin Oncol. 2021;44:580–7. [DOI] [PubMed] [PMC]

16.

Mathelin C, Ame S, Anyanwu S, Avisar E, Boubnider WM, Breitling K, et al. Breast cancer management during the COVID-19 pandemic: the senologic international society survey. Eur J Breast Health. 2021;17:188–96. Erratum in: Eur J Breast Health. 2021;17:296. [DOI] [PubMed] [PMC]

17.

Sood S, Mbarika V, Jugoo S, Dookhy R, Doarn CR, Prakash N, et al. What is telemedicine? A collection of 104 peer-reviewed perspectives and theoretical underpinnings. Telemed J E Health. 2007;13:573–90. [DOI] [PubMed]

18.

Chouinard J. Satellite contributions to telemedicine: Canadian CME experiences. Can Med Assoc J. 1983;128:850–55. [PubMed] [PMC]

19.

Curran VR, Church JG. A study of rural women’s satisfaction with a breast cancer self-help network. J Telemed Telecare. 1999;5:47–54. [DOI] [PubMed]

20.

Olver IN, Selva-Nayagam S. Evaluation of a telemedicine link between Darwin and Adelaide to facilitate cancer management. Telemed J. 2000;6:213–8. [DOI] [PubMed]

21.

Kunkler IH, Prescott RJ, Lee RJ, Brebner JA, Cairns JA, Fielding RG, et al. TELEMAM: a cluster randomised trial to assess the use of telemedicine in multi-disciplinary breast cancer decision making. Eur J Cancer. 2007;43:2506–14. [DOI] [PubMed]

22.

Karim H, Choobineh H, Kheradbin N, Ravandi MH, Naserpor A, Safdari R. Mobile health applications for improving the sexual health outcomes among adults with chronic diseases: a systematic review. Digit Health. 2020;6:2055207620906956. [DOI] [PubMed] [PMC]

23.

Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, et al.; Panel members. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020;31:1320–35. [DOI] [PubMed] [PMC]

24.

Jazieh AR, Chan SL, Curigliano G, Dickson N, Eaton V, Garcia-Foncillas J, et al. Delivering cancer care during the COVID-19 pandemic: recommendations and lessons learned from ASCO global webinars. JCO Glob Oncol. 2020;6:1461–71. [DOI] [PubMed] [PMC]

25.

Pareek P, Vishnoi JR, Kombathula SH, Vyas RK, Misra S. Teleoncology: the youngest pillar of oncology. JCO Glob Oncol. 2020;6:1455–60. [DOI] [PubMed] [PMC]

26.

Tevaarwerk AJ, Chandereng T, Osterman T, Arafat W, Smerage J, Polubriaginof FCG, et al. Oncologist perspectives on telemedicine for patients with cancer: a national comprehensive cancer network survey. JCO Oncol Pract. 2021;17:e1318–26. [DOI] [PubMed] [PMC]

27.

Adelhoefer S, Berning P, Solomon SB, Maybody M, Whelton SP, Blaha MJ, et al. Decreased public pursuit of cancer-related information during the COVID-19 pandemic in the United States. Cancer Causes Control. 2021;32:577–85. [DOI] [PubMed] [PMC]

28.

ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer [Internet]. Lugano: European Society for Medical Oncology; c2023 [cited 2023 Jan 29]. Available from: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/breast-cancer-in-the-covid-19-era

29.

Pelle F, Cappelli S, Graziano F, Piarulli L, Cavicchi F, Magagnano D, et al. Breast cancer surgery during the Covid-19 pandemic: a monocentre experience from the Regina Elena National Cancer Institute of Rome. J Exp Clin Cancer Res. 2020;39:171. [DOI] [PubMed] [PMC]

30.

Brenes Sánchez JM, Picado AL, Olivares Crespo ME, García Sáenz JÁ, De La Plata Merlo RM, De La Muela MH. Breast cancer management during COVID-19 pandemic in Madrid: surgical strategy. Clin Breast Cancer. 2021;21:E128–35. [DOI] [PubMed] [PMC]

31.

Sharp O, Masud D. Breast reconstruction with immediate autologous free tissue transfer in a peri-operative COVID-19 positive patient: a case report illustrating feasibility of aftercare. J Plast Reconstr Aesthet Surg. 2021;74:644–710. [DOI] [PubMed] [PMC]

32.

Yildiz F, Oksuzoglu B. Teleoncology or telemedicine for oncology patients during the COVID-19 pandemic: the new normal for breast cancer survivors? Future Oncol. 2020;16:2191–5. [DOI] [PubMed] [PMC]

33.

Merz V, Ferro A, Piras EM, Zanutto A, Caffo O, Messina C. Electronic medical record–assisted telephone follow-up of breast cancer survivors during the COVID-19 pandemic: a single institution experience. JCO Oncol Pract. 2021;17:e44–52. [DOI] [PubMed]

34.

Ndumele A, Park KU. The impact of COVID-19 on national clinical trials network breast cancer trials. Curr Breast Cancer Rep. 2021;13:103–9. [DOI] [PubMed] [PMC]

35.

Elkaddoum R, Kourie HR, Kassis NE, Khaddage A, Salem C, Nasr E, et al. Treating cancer patients in times of COVID-19 pandemic: a virtual women cancers multidisciplinary meeting experience. Bull Cancer. 2020;107:738–40. [DOI] [PubMed] [PMC]

36.

Bizot A, Karimi M, Rassy E, Heudel PE, Levy C, Vanlemmens L, et al. Multicenter evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic. Br J Cancer. 2021;125:1486–93. [DOI] [PubMed] [PMC]

37.

Mallaiah S, Narayanan S, Wagner R, Cohen C, Christie AJ, Bruera E, et al. Yoga therapy in cancer care via telehealth during the COVID-19 pandemic. Integr Cancer Ther. 2022;21:15347354221141094. [DOI] [PubMed] [PMC]

38.

Brunet F, Malas K, Desrosiers ME. Will telemedicine survive after COVID-19? Healthc Manage Forum. 2021;34:256–9. [DOI] [PubMed]

39.

Henkin JS, Botton CE, Simon MS, Rocha GG, Silveira CB, Gehrke RS, et al. Telehealth multicomponent exercise and health education in breast cancer patients undergoing primary treatment: rationale and methodological protocol for a randomized clinical trial (ABRACE: Telehealth). Trials. 2023;24:42. [DOI] [PubMed] [PMC]

40.

Silva Ferreira I, Carvalho Fernandes AF, Moura Barbosa Castro RC, Rodrigues Bezerra A, Velasco Yanez RJ. Telenursing in the sexual function of women with breast cancer: a study protocol. Medicine (Baltimore). 2022;101:e31449. [DOI] [PubMed] [PMC]

41.

Gordon BR, Qiu L, Doerksen SE, Kanski B, Lorenzo A, Truica CI, et al. Addressing metastatic individuals everyday: rationale and design of the nurse AMIE for Amazon Echo Show trial among metastatic breast cancer patients. Contemp Clin Trials Commun. 2023;32:101058. [DOI] [PubMed] [PMC]

42.

Akingbade O, Adediran V, Somoye IE, Alade AS, Chow KM. Perceived feasibility and usefulness of mHealth interventions for psychoeducational support among Nigerian women receiving chemotherapy for breast cancer: a focus group study. Support Care Cancer. 2022;30:9723–34. [DOI] [PubMed] [PMC]

43.

Colombage UN, Soh SE, Lin KY, Kruger J, Frawley HC. The feasibility of pelvic floor training to treat urinary incontinence in women with breast cancer: a telehealth intervention trial. Breast Cancer. 2023;30:121–30. [DOI] [PubMed] [PMC]

44.

Park HY, Nam KE, Lim JY, Yeo SM, Lee JI, Hwang JH. Real-time interactive digital health care system for postoperative breast cancer patients: a randomized controlled trial. Telemed J E Health. 2023;29:1057–67. [DOI] [PubMed]

45.

Ueland K, Sanchez SC, Rillamas-Sun E, Shen H, Schattenkerk L, Garcia G, et al. A digital health intervention to improve nutrition and physical activity in breast cancer survivors: rationale and design of the Cook and Move for Your Life pilot and feasibility randomized controlled trial. Contemp Clin Trials. 2022;123:106993. [DOI] [PubMed]

46.

Malek Pascha VA, Sun L, Gilardino R, Legood R. Telemammography for breast cancer screening: a cost-effective approach in Argentina. BMJ Health Care Inform. 2021;28:e100351. [DOI] [PubMed] [PMC]

47.

Elsheakh DN, Mohamed RA, Fahmy OM, Ezzat K, Eldamak AR. Complete breast cancer detection and monitoring system by using microwave textile based antenna sensors. Biosensors (Basel). 2023;13:87. [DOI] [PubMed] [PMC]

48.

Beatty L, Kemp E, Butow P, Girgis A, Hulbert-Williams N, Kaambwa B, et al.; FMW-A Authorship Group; Koczwara B. Finding My Way-advanced: can a web-based psychosocial intervention improve the mental quality of life for women with metastatic breast cancer vs attention-control? Study protocol of a randomised controlled trial. BMC Cancer. 2022;22:1353. [DOI] [PubMed] [PMC]

49.

Shaver J. The state of telehealth before and after the COVID-19 pandemic. Prim Care. 2022;49:517–30. [DOI] [PubMed] [PMC]

50.

Buse CR, Kelly EAO, Muss HB, Nyrop KA. Perspectives of older women with early breast cancer on telemedicine during post-primary treatment. Support Care Cancer. 2022;30:9859–68. [DOI] [PubMed] [PMC]

51.

Du S, Carfang L, Restrepo E, Benjamin C, Epstein MM, Fairley R, et al. Patient-reported experiences of breast cancer screening, diagnosis, and treatment delay, and telemedicine adoption during COVID-19. Curr Oncol. 2022;29:5919–32. [DOI] [PubMed] [PMC]

52.

Miziara RA, Maesaka JY, Matsumoto DRM, Penteado L, Anacleto AADS, Accorsi TAD, et al. Teleoncology orientation of low-income breast cancer patients during the COVID-19 pandemic: feasibility and patient satisfaction. Rev Bras Ginecol Obstet. 2021;43:840–6. [DOI] [PubMed] [PMC]

53.

Neeman E, Lyon L, Sun H, Conell C, Reed M, Kumar D, et al. Future of teleoncology: trends and disparities in telehealth and secure message utilization in the COVID-19 era. JCO Clin Cancer Inform. 2022;6:e2100160. [DOI] [PubMed] [PMC]

54.

Pandya A, Waller M, Portnoy JM. The regulatory environment of telemedicine after COVID-19. J Allergy Clin Immunol Pract. 2022;10:2500–5. [DOI] [PubMed] [PMC]

55.

Schade EC, Elkaddoum R, Kourie HR. The psychological challenges for oncological patients in times of COVID-19 pandemic: telemedicine, a solution? Future Oncol. 2020;16:2265–8. [DOI] [PubMed] [PMC]